Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Targeted Search
Clinical Trials Search Results
Query: "AREA[SponsorSearch](Heptares Therapeutics Limited)"
Count: 14
Selected: 0
| NCT ID | Title |
|---|
| NCT02546310 | Phase 1 Study Investigating Effects of HTL0009936 on Cognition and BOLD fMRI Signals in Healthy Elderly Subjects | ||
| NCT04941989 | A Study in Healthy Subjects to Assess the Safety, Tolerability and Pharmacokinetics of HTL0022562 | ||
| NCT04935320 | Comparison of Blood Levels of HTL0016878 From an Oral Capsule and an Oral Solution | ||
| NCT04849286 | Measurement of HTL0016878 in Cerebrospinal Fluid | ||
| NCT04462263 | Study to Investigate the Receptor Occupancy of HTL0014242 Using [18F] FPEB in Healthy Male Subjects | ||
| NCT03847207 | A Study in Healthy Subjects to Assess the Safety, Tolerability, PK and PD of HTL0030310 | ||
| NCT03785054 | Phase 1, Healthy Subject, Safety, Tolerability and Pharmacokinetic Study of mGlu5 NAM HTL0014242 | ||
| NCT03592862 | A Study to Assess Safety, Tolerability, and Efficacy of HTL0018318 in Patients With Dementia With Lewy Bodies | ||
| NCT03456349 | Multi-centre Study of HTL0018318 in Patients as an add-on to Standard-of-care | ||
| NCT03244228 | A Two Part Study to Assess Safety, PK, PD, and Food Effect of Oral HTL0016878 | ||
| NCT03198624 | Pharmacokinetics of Oral Capsule in Healthy Japanese vs. Caucasian Subjects | ||
| NCT02958696 | Relative Bioavailability of HTL0018318 Oral Aqueous Solution Versus Capsules | ||
| NCT02710188 | Relative Bioavailability Study in Healthy Subjects to Evaluate the Pharmacokinetics of HTL0009936 After One Dose of Prototype Formulation | ||
| NCT02291783 | Phase I, Healthy Subject, Safety, Tolerability and Pharmacokinetic Study of an M1 Agonist to Treat Cognitive Impairment |
